Results 241 to 250 of about 101,548 (353)

Effects of GLP‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

open access: yes
International Journal of Dermatology, EarlyView.
Miranda K. Branyiczky   +4 more
wiley   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

open access: yesJournal of Internal Medicine, EarlyView.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings. [PDF]

open access: yesJ Orthop Surg Res
Ugur F   +8 more
europepmc   +1 more source

Tirzepatide‐induced body composition changes: Implications from the SURPASS‐3 MRI substudy

open access: yes
Journal of Diabetes Investigation, EarlyView.
I‐Weng Yen, Hung‐Yuan Li
wiley   +1 more source

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell   +11 more
wiley   +1 more source

Prevalence and Factors Associated With Symptom Profiles of Disorders of Gut‐Brain Interaction in Obesity Before and After Treatment

open access: yesNeurogastroenterology &Motility, EarlyView.
DGBI symptoms are common in obesity and have the potential to exacerbate negative health outcomes. In general, the prevalence of DGBI symptoms decreases after obesity treatment, but patients can also shift from one GI symptom profile to another. ABSTRACT Background & Aims Disorders of gut‐brain interaction (DGBI) in obesity could impair health outcomes.
Esther Colomier   +11 more
wiley   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

open access: yesObesity Reviews, EarlyView.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source

Home - About - Disclaimer - Privacy